Skip to search formSkip to main contentSkip to account menu

DEBIO1143

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.
2531 Background: Inhibitors of apoptosis proteins (IAPs) play a critical role in modulating multiple processes, including… 
2014
2014
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
7029 Background: Treatment of AML remains difficult due to the development of treatment resistance. Inhibitors of apoptosis… 
2014
2014
First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.
2532 Background: Inhibitors of apoptosis proteins (IAPs) modulate multiple processes, including caspases activation and NF-κB… 
2014
2014
A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
TPS6097^ Background: Inhibitors of apoptosis proteins (IAPs) are negative modulators of apoptosis which represent attractive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)